| Literature DB >> 31071139 |
Chun-You Chen1, Shih-Chang Hsu2,3, Hui-Ling Hsieh4,5, Chi-Won Suk6, Yuan-Pin Hsu2,3,7, Yuh-Mou Sue4, Tso-Hsiao Chen4, Feng-Yen Lin8,9, Chun-Ming Shih8,9, Jaw-Wen Chen10,11,12,13, Shing-Jong Lin10,11,12,14,15, Po-Hsun Huang10,11,14, Chung-Te Liu4,7,8.
Abstract
BACKGROUND: Patients with renal impairment have altered immunity, which might cause vulnerability to specific pathogens and worsen pneumonia-related outcomes. Nonetheless, the microbiological features of pneumonia in patients with decreased renal function remain unknown.Entities:
Mesh:
Year: 2019 PMID: 31071139 PMCID: PMC6508684 DOI: 10.1371/journal.pone.0216367
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic and laboratory characteristics of patients hospitalized with pneumonia.
| Characteristics | Total | Survival | Mortality | |
|---|---|---|---|---|
| n = 1554 | n = 1392 | n = 162 | ||
| Male | 987 (63.5%) | 877 (63.0%) | 110 (67.9%) | 0.220 |
| Age (years) | 76.1 ± 16.7 | 75.3 ± 17.0 | 83.1 ± 11.2 | < 0.001 |
| CKD | 441 (28.4%) | 376 (27.0%) | 65 (40.1%) | <0.001 |
| AKI | 298 (19.2%) | 242 (17.4%) | 56 (34.6%) | < 0.001 |
| ACKI | 114 (7.3%) | 91 (6.5%) | 23 (14.2%) | <0.001 |
| ESRD | 79 (5.1%) | 65 (4.7%) | 14 (8.7%) | 0.028 |
| DM | 110 (7.1%) | 104 (7.5%) | 6 (3.7%) | 0.077 |
| CHF | 111 (7.1%) | 96 (6.9%) | 15 (9.3%) | 0.269 |
| COPD | 102 (6.6%) | 93 (6.7%) | 9 (5.6%) | 0.584 |
| BUN (mg/dL) | 20 (13, 32) | 19 (13, 29) | 37 (22, 61) | < 0.001 |
| Creatinine (mg/dL) | 0.9 (0.7, 1.4) | 0.9 (0.7, 1.3) | 1.3 (0.8, 2.3) | < 0.001 |
| eGFR (mL/min/1.73 m2) | 77.1 (48.6, 93.6) | 78.5 (52.8, 94.5) | 53.0 (26.7, 81.9) | < 0.001 |
| AST (U/L) | 25 (19, 35) | 24 (19, 33) | 33 (22, 51) | < 0.001 |
| ALT (U/L) | 19 (13, 29) | 18 (13, 28) | 23 (14, 43) | < 0.001 |
| Albumin (g/dL) | 2.9(2.5, 3.3) | 3.0(2.6, 3.4) | 2.5(2.2, 2.9) | < 0.001 |
| Hemoglobin (g/dL) | 11.8±2.2 | 11.9±2.1 | 10.6±2.5 | < 0.001 |
| WBC (103/mm3) | 12.7 ± 6.2 | 12.6 ± 6.0 | 13.9 ± 8.1 | 0.035 |
| Neutrophil (cell/mm3) | 9375 (6315, 13022) | 9297 (6306, 12927) | 9909 (6585, 14425) | 0.132 |
| Lymphocyte (cell/mm3) | 1080 (642, 1618) | 1100 (669, 1638) | 836 (458, 1443) | < 0.001 |
| Monocyte (cell/mm3) | 679 (424, 1013) | 685 (433, 1010) | 629 (377, 1067) | 0.390 |
| NLR | 8.5 (4.9, 15.4) | 8.4 (4.9, 14.8) | 10.6 (5.2, 24.9) | <0.004 |
| MLR | 0.6 (0.4, 1.0) | 0.6 (0.4, 1.0) | 0.7 (0.4, 1.3) | 0.026 |
| Platelet (103/mm3) | 211 (160, 277) | 209 (161, 278.5) | 226 (134, 276) | 0.607 |
| Bacteremia | 91 (5.9%) | 72 (5.2%) | 19 (11.7%) | < 0.001 |
| Ventilator use | 271 (17.4%) | 190 (13.7%) | 81 (50.0%) | < 0.001 |
| ICU admission | 238 (15.3%) | 182 (13.1%) | 56 (34.6%) | < 0.001 |
| Hospital days (days) | 11 (7, 18) | 10 (7, 17) | 15 (6, 30) | < 0.002 |
| SMART-COP score | 3 (2, 4) | 2 (2, 3) | 4 (3, 6) | <0.001 |
| CURB65 score | 2 (1, 2) | 2 (1, 2) | 2 (2, 3) | <0.001 |
ǂby Exact Wilcoxon two-sample test.
CKD, chronic kidney disease; AKI, acute kidney injury; ACKI, acute-on-chronic kidney injury; DM, diabetes mellitus; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; BUN, blood urea nitrite; eGFR, estimated glomerular filtration rate; WBC, white blood cell count; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase. Continuous variables with normal distribution were expressed as mean ± standard deviation, while those deviated from normal distribution were expressed as medium (1st, 3rd quartile).
Fig 1Risk factors for in-hospital mortality in patients with pneumonia.
Odds ratio for mortality was calculated by multivariate logistic regression. DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase, CI, confidence interval.
Sputum microbiological analysis of patients hospitalized with pneumonia categorized by eGFR.
| Characteristics | Total | eGFR≧55 | eGFR<55 | |
|---|---|---|---|---|
| 207 (15.1%) | 163 (17.0%) | 44 (10.8%) | 0.004 | |
| 185 (13.5%) | 115 (11.9%) | 70 (17.2%) | 0.010 | |
| 67 (4.9%) | 45 (4.7%) | 22 (5.4%) | 0.572 | |
| 62 (4.5%) | 36 (3.7%) | 26 (6.4%) | 0.032 | |
| 45 (3.3%) | 37 (3.8%) | 8 (2.0%) | 0.074 | |
| 40 (2.9%) | 33 (3.4%) | 7 (1.7%) | 0.085 | |
| 23 (1.7%) | 19 (2.0%) | 4 (1.0%) | 0.191 | |
| 22 (1.6%) | 18 (1.9%) | 4 (1.0%) | 0.231 | |
| 105 (7.7%) | 62 (6.4%) | 43 (10.5%) | 0.009 | |
| 11 (0.8%) | 7 (0.7%) | 4 (1.0%) | 0.741 | |
| 43 (3.1%) | 31 (3.2%) | 12 (2.9%) | 0.787 | |
| 140 (10.2%) | 111 (11.5%) | 29 (7.1%) | 0.014 | |
| 39 (2.8%) | 21 (2.2%) | 18 (4.4%) | 0.023 | |
| 579 (42.2%) | 408 (42.4%) | 171 (41.9%) | 0.876 |
ǂby Fisher’s Exact test.
eGFR, estimated glomerular filtration rate; GNB, gram-negative bacillus; Ps. aeruginosa, Pseudomonas aeruginosa; Kl. pneumoniae, Klebsiella pneumoniae; GPC, gram-positive coccus; S. aureus, Staphylococcus aureus; Strep., Streptococcus; WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio.
Fig 2Risk of isolation of specific pathogens in patients with eGFR of < 55.3 mL/min/1.73 m2.
Odds ratios for specific pathogens were calculated using a multivariate logistic regression model adjusted by age and gender. CI, confidence interval; eGFR, estimated glomerular filtration rate; Ps. aeruginosa, Pseudomonas aeruginosa; Kl. pneumoniae, Klebsiella pneumoniae; S. aureus, Staphylococcus aureus; Strep., Streptococcus.
The immune cell profiles of patients hospitalized with pneumonia categorized by eGFR.
| Immune cells | Total | eGFR ≥ 55 | eGFR < 55 | |
|---|---|---|---|---|
| WBC (103/mm3) | 12.8 ± 6.4 | 12.6 ± 6.1 | 13.1 ± 7.0 | 0.215 |
| Platelet (103/mm3) | 213 (161, 279) | 221 (171, 290) | 193.5 (150, 251) | <0.001 |
| Neutrophil (cell/mm3) | 9418 (6315, 13422) | 9287 (6270, 12935) | 9568 (6413, 13984) | 0.139 |
| Eosinophil (cell/mm3) | 32.6 (0, 130.1) | 3.8 (0, 143.3) | 21.3 (0, 96.1) | 0.001 |
| Basophil (cell/mm3) | 22 (0, 48) | 24 (0, 52) | 16 (0, 42) | <0.001 |
| Lymphocyte (cell/mm3) | 1080 (642, 1623) | 1114 (685, 1689) | 944 (545, 1425) | <0.001 |
| Monocyte (cell/mm3) | 675 (426, 1013) | 676 (438, 1015) | 675 (394, 1012) | 0.438 |
| NLR | 8.6 (4.9, 15.3) | 8.2 (4.7, 14.3) | 9.9 (5.3, 18.2) | <0.001 |
| MLR | 0.6 (0.4, 1.0) | 0.6 (0.4, 1.0) | 0.7 (0.4, 1.2) | 0.001 |
ǂby Exact Wilcoxon two-sample test.
eGFR, estimated glomerular filtration rate; WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio. Continuous variables with normal distribution were expressed as mean ± standard deviation, while those deviated from normal distribution were expressed as medium (1st, 3rd quartile).
Fig 3The association between immune cell profiles and mortality in patients hospitalized with pneumonia.
A. The odds ratios for mortality in patients with eGFR ≥ 55 mL/min/1.73 m2. B. The odds ratios for mortality in patients with eGFR < 55 mL/min/1.73 m2. WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio.
Characteristics and outcomes associated with S. aureus in sputum.
| Characteristics | Without | With | |
|---|---|---|---|
| Age (year) | 76.0 ± 16.7 | 79.7 ± 14.8 | 0.029 |
| Male | 808 (63.8%) | 71 (67.6%) | 0.436 |
| CKD | 351 (27.7%) | 43 (41.0%) | 0.004 |
| AKI | 230 (18.2%) | 22 (21.0%) | 0.479 |
| ACKI | 80 (6.3%) | 13 (12.4%) | 0.018 |
| DM | 85 (6.7%) | 7 (6.7%) | 0.985 |
| CHF | 92 (7.3%) | 3 (2.7%) | 0.087 |
| COPD | 94 (7.4%) | 5 (4.8%) | 0.311 |
| Hemoglobin (g/dL) | 11.8 ± 2.2 | 11.6 ± 2.2 | 0.234 |
| BUN (mg/dL) | 20 (13, 31) | 27 (16, 46) | < 0.001 |
| Creatinine (mg/dL) | 0.9 (0.7, 1.3) | 1.0 (0.7, 1.6) | 0.105 |
| eGFR (mL/min/m2) | 78.2 (50.7, 93.9) | 69.2 (40.5, 86.3) | 0.020 |
| AST (U/L) | 25 (19, 35) | 25 (19, 37) | 0.294 |
| ALT (U/L) | 18 (12, 29) | 21.5 (13, 33) | 0.076 |
| Albumin (g/dL) | 2.9 (2.5, 3.3) | 2.7 (2.5, 2.9) | < 0.003 |
| WBC (103/mm3) | 12.7 ± 6.2 | 13.6 ± 7.7 | 0.221 |
| Neutrophil (cell/mm3) | 9360 (6310, 13163) | 9809 (6488, 15059) | 0.159 |
| Lymphocyte (cell/mm3) | 1094 (652, 1644) | 810 (500, 1339) | 0.004 |
| Monocyte (cell/mm3) | 685 (437, 1014) | 592 (330, 963) | 0.074 |
| NLR | 8.4 (4.8, 15.0) | 10.5 (6.9, 21.2) | 0.002 |
| MLR | 0.6 (0.4, 1.0) | 0.7 (0.4, 1.2) | 0.251 |
| Bacteremia | 68 (5.4%) | 8 (7.6%) | 0.333 |
| Ventilator use | 229 (18.1%) | 28 (26.7%) | 0.030 |
| ICU admission | 198 (15.6%) | 29 (27.6%) | 0.002 |
| Hospital days (day) | 11 (7, 18) | 14 (10, 25) | < 0.010 |
| Mortality | 128 (10.1%) | 19 (18.1%) | 0.011 |
| SMART-COP | 3 (2, 4) | 3 (2, 4) | 0.255 |
| CURB65 | 2 (1, 2) | 2 (1, 3) | <0.001 |
ǂby Exact Wilcoxon two-sample test.
S. aureus, Staphylococcus aureus; CKD, chronic kidney disease; AKI, acute kidney injury; ACKI, acute-on-chronic kidney injury; DM, diabetes mellitus; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; BUN, blood urea nitrite; eGFR, estimated glomerular filtration rate; WBC, white blood count; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ICU, intensive care unit. Continuous variables with normal distribution were expressed as mean ± standard deviation, while those deviated from normal distribution were expressed as medium (1st, 3rd quartile).
Resistance to methicillin of S. aureus and the outcomes of pneumonia patients.
| Character | P value | ||
|---|---|---|---|
| Number | 42 (40.0%) | 63 (60.0%) | n/a |
| Age (year) | 79.8±15.3 | 79.7±14.5 | 0.96 |
| Male | 23 (54.8%) | 48 (76.2%) | 0.02 |
| CKD | 15 (35.7%) | 28 (44.4%) | 0.37 |
| AKI | 7 (16.7%) | 15 (23.8%) | 0.38 |
| eGFR (mL/min/1.73m2) | 78.5 (50.1, 86.6) | 62.1 (26.8, 85.3) | 0.22 |
| Empirical treatment | n/a | ||
| Piperacillin/tazobactam | 14 (33.3%) | 28 (44.4%) | |
| Amoxicillin/clavulanate | 10 (23.8%) | 6 (9.6%) | |
| 2nd cephalosporines | 0 (0%) | 1 (1.6%) | |
| 3rd cephalosporines | 5 (11.9%) | 8 (12.7%) | |
| 4th cephalosporines | 1 (2.4%) | 0 (0%) | |
| Quinolones | 9 (21.4%) | 9 (14.3%) | |
| Carbapenems | 3 (7.1%) | 11 (17.5%) | |
| Teioplanin | 1 (2.4%) | 1 (1.6%) | |
| Inappropriate empirical treatment | 2 (4.8%) | 61 (96.8%) | <0.01 |
| Hospital days (day) | 13.5 (10, 24) | 15 (10, 26) | 0.91 |
| ICU admission | 10 (23.8%) | 19 (30.2%) | 0.48 |
| Ventilator | 13 (31.0%) | 15 (23.8%) | 0.42 |
| Mortality | 10 (23.8%) | 9 (14.3%) | 0.21 |
S. aureus, Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; CKD, chronic kidney disease; AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; ICU, intensive care unit. Continuous variables with normal distribution were expressed as mean ± standard deviation, while those deviated from normal distribution were expressed as medium (1st, 3rd quartile).